Qiagen (NYSE:QGEN) Rating Lowered to “Neutral” at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) was downgraded by JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $52.00 price target on the stock, down from their previous price target of $55.00. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 3.37% from the company’s previous close.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings raised Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a research report on Friday, August 7th. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. UBS Group assumed coverage on shares of Qiagen in a research report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 price objective on the stock. Finally, Berenberg Bank set a $45.50 price objective on Qiagen and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus price target of $46.09.

Qiagen Price Performance

Qiagen stock traded up $0.14 during midday trading on Thursday, reaching $50.31. The company’s stock had a trading volume of 4,534,882 shares, compared to its average volume of 2,776,567. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. Qiagen has a 52 week low of $32.53 and a 52 week high of $57.81. The business has a 50-day moving average price of $44.73 and a 200-day moving average price of $42.70. The stock has a market cap of $10.37 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 5.01 and a beta of 0.61.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, sell-side analysts predict that Qiagen will post 2.44 EPS for the current year.

Hedge Funds Weigh In On Qiagen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Amundi lifted its holdings in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after acquiring an additional 524,959 shares during the last quarter. State Street Corp boosted its position in Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after purchasing an additional 93,575 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Qiagen by 20.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock valued at $66,649,000 after acquiring an additional 286,665 shares during the last quarter. Swiss National Bank lifted its stake in shares of Qiagen by 21.1% in the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock worth $28,686,000 after acquiring an additional 124,920 shares during the period. Finally, Arbejdsmarkedets Tillaegspension boosted its holdings in shares of Qiagen by 24.8% during the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company’s stock worth $25,502,000 after purchasing an additional 126,405 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.